HEXABRIX
Clinical safety rating
cautionComprehensive clinical and safety monograph for HEXABRIX (HEXABRIX).
Hexabrix is an ionic, high-osmolar iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast during radiographic procedures. Its mechanism is physical rather than pharmacological, based on iodine's atomic number and density.
| Metabolism | Not metabolized; eliminated unchanged via glomerular filtration by the kidneys. |
| Excretion | Renal: 95% unchanged via glomerular filtration; Biliary: <5%; Fecal: <1% |
| Half-life | Terminal elimination half-life: 1.5–2 hours in adults (prolonged in renal impairment; up to 30 hours in severe CKD) |
| Protein binding | Negligible (<5%); no specific binding proteins |
| Volume of Distribution | 0.3–0.4 L/kg (confined to extracellular space; does not cross intact blood-brain barrier) |
| Bioavailability | Intravenous/Intra-arterial: 100%; Oral: 0% (not absorbed) |
| Onset of Action | Intravenous: immediate (within seconds); Intra-arterial: immediate; Oral: not applicable (no GI absorption) |
| Duration of Action | Diagnostic opacification: 15–30 minutes for CT; up to 60 minutes for angiography; prolonged in renal impairment due to delayed clearance |
| Molecular Weight | 1269.2 Da |
Intravenous: 0.3-0.6 mL/kg (maximum 100 mL) for urography; 40-80 mL for CT enhancement.
| Dosage form | INJECTABLE |
| Renal impairment | Contraindicated in patients with GFR <30 mL/min/1.73m². For GFR 30-59 mL/min, reduce dose by 50% and ensure adequate hydration. |
| Liver impairment | No specific Child-Pugh based adjustments; use caution in severe hepatic impairment due to risk of hepatorenal syndrome. |
| Pediatric use | Intravenous: 0.5-1 mL/kg (maximum 2 mL/kg) for urography; not recommended for neonates due to risk of acute renal failure. |
| Geriatric use | Reduce dose by 25-50% in patients >70 years; maintain hydration and monitor renal function. |
| 1st trimester | Iodinated contrast media like HEXABRIX are generally avoided in the first trimester due to theoretical risks of fetal hypothyroidism; however, no teratogenic effects have been established in humans. |
| 2nd trimester | Use only if clearly needed; minimal fetal exposure expected due to rapid renal elimination, but neonatal thyroid function should be checked postnatally if used. |
| 3rd trimester | Use only if clearly needed; risk of transient neonatal hypothyroidism due to excess iodide crossing placenta, especially near term. |
Clinical note
Comprehensive clinical and safety monograph for HEXABRIX (HEXABRIX).
| Placental transfer | Limited across human placenta; small amounts cross due to low molecular weight and water solubility, but fetal exposure is minimal with standard doses. |
| Breastfeeding | HEXABRIX is excreted into breast milk in very small amounts (<1% of maternal dose). The risk to infant is negligible, but a pragmatic approach is to pump and discard milk for 24 hours post-administration. |
| Lactation Rating | L2 (probably compatible) per LactMed |
| Teratogenic Risk | HEXABRIX (ioxaglate meglumine and ioxaglate sodium) is an iodinated contrast agent. In animal studies, no teratogenic effects were observed. In humans, there is no evidence of fetal harm from diagnostic doses, though theoretical risks from free iodide exist, especially in the third trimester. The American College of Radiology recommends use only if clearly needed, with minimal dose. |
| Fetal Monitoring | Monitor maternal renal function (serum creatinine) and hydration status. Assess for allergic reactions. Fetal monitoring is not routinely required, but consider fetal heart rate monitoring if there is a risk of fetal hypoxia from maternal hypotension. |
| Fertility Effects | No known adverse effects on fertility in animal or human studies. |
■ FDA Black Box Warning
Risk of severe, life-threatening adverse reactions including anaphylaxis, cardiovascular collapse, and seizures. Use only when diagnostic information is essential. Resuscitative equipment and trained personnel must be immediately available.
| Common Effects | Application site reactions burning irritation itching and redness Dry skin |
| Serious Effects |
Hypersensitivity to ioxaglic acid or any excipientManifest hyperthyroidismDecompensated cardiac insufficiencyHysterosalpingography in pregnancy or suspected pregnancy
| Precautions | Risk of acute renal failure, particularly in patients with pre-existing renal impairment, diabetes, or dehydration. Caution in patients with cardiovascular disease, asthma, or known hypersensitivity. Avoid extravasation. Thyroid function tests may be affected. Ensure adequate hydration before and after administration. |
| Food/Dietary | No specific food interactions. Maintain adequate hydration; alcohol should be avoided as it may increase dehydration risk. |
| Clinical Pearls | HEXABRIX (ioxaglate meglumine and ioxaglate sodium) is a low-osmolar, ionic, dimeric contrast medium used for intravascular administration. It has lower osmolality than conventional ionic monomers, reducing the risk of contrast-induced nephropathy and hemodynamic disturbances. Ensure adequate hydration before and after administration. Caution in patients with renal impairment, diabetes, multiple myeloma, or prior contrast reactions. Do not mix with other drugs. Monitor for delayed hypersensitivity reactions. |
| Patient Advice | Inform your doctor if you have kidney disease, diabetes, or any allergies, especially to contrast agents. · Drink plenty of fluids before and after the procedure to stay hydrated. · You may experience a warm sensation or metallic taste during injection; this is normal. · Report any symptoms like hives, itching, difficulty breathing, or swelling after the scan. · If you take metformin, you may need to stop it temporarily as directed by your doctor. |
Loading safety data…